These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 22434242)

  • 1. Race and the prognostic influence of p53 in women with breast cancer.
    Dookeran KA; Dignam JJ; Holloway N; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
    Ann Surg Oncol; 2012 Jul; 19(7):2334-44. PubMed ID: 22434242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 as a marker of prognosis in African-American women with breast cancer.
    Dookeran KA; Dignam JJ; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
    Ann Surg Oncol; 2010 May; 17(5):1398-405. PubMed ID: 20049641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
    Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
    Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
    Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
    Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.
    Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI
    J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
    Purrington KS; Gorski D; Simon MS; Hastert TA; Kim S; Rosati R; Schwartz AG; Ratnam M
    Breast Cancer Res Treat; 2020 May; 181(1):145-154. PubMed ID: 32236827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea.
    Lee JS; Oh M; ;
    Clin Breast Cancer; 2014 Dec; 14(6):426-34. PubMed ID: 25034438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
    Roseland ME; Schwartz K; Ruterbusch JJ; Lamerato L; Krajenta R; Booza J; Simon MS
    Breast Cancer Res Treat; 2017 Aug; 165(1):163-168. PubMed ID: 28547656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does race predict survival for women with invasive breast cancer?
    Walsh SM; Zabor EC; Stempel M; Morrow M; Gemignani ML
    Cancer; 2019 Sep; 125(18):3139-3146. PubMed ID: 31206623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p53 Breast Cancer in Kurdish Women in the West of Iran: a Reverse Correlation with Lymph Node Metastasis.
    Payandeh M; Sadeghi M; Sadeghi E; Madani SH
    Asian Pac J Cancer Prev; 2016; 17(3):1261-4. PubMed ID: 27039757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
    Liu Y; West R; Weber JD; Colditz GA
    Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
    Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
    J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
    JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.
    Conway K; Edmiston SN; Tse CK; Bryant C; Kuan PF; Hair BY; Parrish EA; May R; Swift-Scanlan T
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):921-30. PubMed ID: 25809865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.